Zwie'Bak Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 26-06-2024
- Paid Up Capital ₹ 0.50 M
as on 26-06-2024
- Company Age 21 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
as on 26-06-2024
- Satisfied Charges ₹ 1.20 M
as on 26-06-2024
- Revenue -40.39%
(FY 2020)
- Profit 5.49%
(FY 2020)
- Ebitda 91.41%
(FY 2020)
- Net Worth 17.78%
(FY 2020)
- Total Assets 11.26%
(FY 2020)
About Zwie'Bak Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.00 M. The company has closed loans amounting to ₹1.20 M, as per Ministry of Corporate Affairs (MCA) records.
Shailendra Singh and Poonam Singh serve as directors at the Company.
- CIN/LLPIN
U24232UP2003PTC028068
- Company No.
028068
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Nov 2003
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Aligarh, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Zwie'Bak Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shailendra Singh  | Director | 29-Jun-2016 | Current |
| Poonam Singh | Director | 17-Nov-2003 | Current |
Financial Performance of Zwie'Bak Pharmaceuticals.
Zwie'Bak Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 40.39% decrease. The company also saw a slight improvement in profitability, with a 5.49% increase in profit. The company's net worth Soared by an impressive increase of 17.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zwie'Bak Pharmaceuticals?
In 2019, Zwie'Bak Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Jun 2016 | ₹2.00 M | Open |
State Bank Of India Creation Date: 27 Jan 2011 | ₹1.20 M | Satisfied |
How Many Employees Work at Zwie'Bak Pharmaceuticals?
Unlock and access historical data on people associated with Zwie'Bak Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zwie'Bak Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zwie'Bak Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
